{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"40"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"37"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"35"}],"title":"Failures"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"110"},{"groupId":"OG002","value":"112"},{"groupId":"OG003","value":"112"}],"units":"Participants"}],"description":"Assessed by Response Evaluation Criteria in Solid Tumors (RECIST). Both target and, in the event of multifocal or multicentric invasive breast cancer, nontarget lesions should be followed clinically and their clinical size recorded at aseline. Measurements thereafter are required at the completion of 12 weeks of paclitaxel or paclitaxel/carboplatin and at the completion of all neoadjuvant chemotherapy. At any time point, these lesions should be categorized regarding whether there is evidence of progression. If \"yes\", the study chair should be notified in order to determine whether the patient should come off protocol treatment. In-situcarcinoma does not represent a non-target lesion and should not be recorded or followed.","groups":[{"description":"Patients receive paclitaxel (pac) IV over 60 minutes once weekly in weeks 1-12. Patients then receive dose-dense doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 5-30 minutes (ddAC) once in weeks 13, 15, 17, and 19.\n\ndoxorubicin hydrochloride: Given IV\n\npaclitaxel: Given IV\n\ncyclophosphamide: Given IV","id":"OG000","title":"Arm 1 (Pac --> ddAC)"},{"description":"Patients receive pac and ddAC as in arm 1. Patients also receive bevacizumab (bev) IV over 30-90 minutes in weeks 1, 3, 5, 7, 9, 11, 13, 15, and 17.\n\ndoxorubicin hydrochloride: Given IV\n\npaclitaxel: Given IV\n\ncyclophosphamide: Given IV\n\nbevacizumab: Given IV","id":"OG001","title":"Arm 2 (Pac + Bev --> ddAC + Bev)"},{"description":"Patients receive pac and ddAC as in arm 1. Patients also receive carboplatin IV over 30 minutes once in weeks 1, 4, 7, and 10.\n\ndoxorubicin hydrochloride: Given IV\n\npaclitaxel: Given IV\n\ncyclophosphamide: Given IV\n\ncarboplatin: Given IV","id":"OG002","title":"Arm 3 (Pac + Carboplatin --> ddAC)"},{"description":"Patients receive pac and ddAC as in arm 1, bev as in arm 2, and carboplatin as in arm 3.\n\ndoxorubicin hydrochloride: Given IV\n\npaclitaxel: Given IV\n\ncyclophosphamide: Given IV\n\nbevacizumab: Given IV\n\ncarboplatin: Given IV","id":"OG003","title":"Arm 4 (Pac + Carboplatin + Bev --> ddAC + Bev)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Baseline; at completion of neoadjuvant therapy","title":"Clinical Response Assessed by Tumor Measurement","type":"SECONDARY","unitOfMeasure":"Participants"}